RayKnowChina Research Map
Shortlist

ShanghaiFudan University

Eye & ENT Hospital of Fudan University

复旦大学附属眼耳鼻喉科医院

Listed for 7 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Eye & ENT Hospital of Fudan University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌32 papers led4 open trials led
  2. Retinoblastoma视网膜母细胞瘤6 papers led3 open trials led
  3. Chordoma脊索瘤0 papers led
  4. Neuroblastoma神经母细胞瘤5 papers led1 open trial led
  5. Takayasu arteritis大动脉炎0 papers led
  6. Behçet disease白塞病0 papers led
  7. Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led

Not listed for: Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Osteosarcoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 32 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 1.4%.

Papers led
32
2021–2025
Trials led
10
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 6620212022: 2220222023: 8820232024: 7720242025: 992025

10 hospitals in Shanghai for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07781358

    Age 18 years to 80 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan UniversityShanghai

  2. Recruiting
    Adjuvant vs Surgery Only in Early-stage Recurrent NPC
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06228079

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

  3. Recruiting
    Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
    Phase
    Phase 3
    Started
    2024-07
    Registry
    NCT06235203

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

  4. Not yet recruiting
    Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04215510

    Age 18 years to 70 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 3 listed hospitals as study sitesFuzhou, Nanchang, Shanghai

  5. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  6. Recruiting
    Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07303023

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Chongqing, Hangzhou, Shanghai

  7. Recruiting
    Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07311772

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueImaging & AI
Departments in papersENT / head & neck surgeryRadiation oncologyRadiology / nuclear medicineOphthalmology / neuro-ophthalmology
Papers it led32
  1. Machine learning for predicting distant metastasis in nasopharyngeal carcinoma patients.2025Frontiers in immunologyFree full text
  2. EC-IC Bypass for Skull Base Necrosis and ICA Rupture Hemorrhage After Radiotherapy for Nasopharyngeal Carcinoma.2025Head & neck
  3. Mucosal Flap Reconstruction Enhances Survival in Salvage Endoscopic Nasopharyngectomy for Recurrent Nasopharyngeal Carcinoma: A Propensity-Matched Cohort Study.2025International forum of allergy & rhinology
  4. Down-regulation of PCK2 enhanced the radioresistance phenotype of nasopharyngeal carcinoma.2025International journal of radiation biology
  5. Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: a randomized clinical trial.2025Journal for immunotherapy of cancerRCTFree full text
  6. A prospective cross-sectional-comparative analysis of nutrition screening and assessment tools in chinese nasopharyngeal carcinoma inpatients undergoing radiotherapy using Global Leadership Initiative on Malnutrition criteria as the gold st2025Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
  7. Feasibility of modified target volumes to meet potential therapeutic needs for nasopharyngeal carcinoma.2025Radiography (London, England : 1995)
  8. A qualitative analysis of fear of cancer recurrence among Chinese nasopharyngeal cancer patients who are undergoing active treatment.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFree full text
  9. Artificial intelligence-assisted detection of nasopharyngeal carcinoma on endoscopic images: a national, multicentre, model development and validation study.2025The Lancet. Digital health
  10. Neoadjuvant chemotherapy for organ preservation in sinonasal squamous cell carcinoma.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  11. Magnetic resonance imaging based on radiomics for differentiating T1-category nasopharyngeal carcinoma from nasopharyngeal lymphoid hyperplasia: a multicenter study.2024Japanese journal of radiology
  12. Bilateral Oculomotor Ocular Neuromyotonia-A Rare Case Due to Nasopharyngeal Carcinoma Radiotherapy.2024Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  13. Identifying biomarkers for nasopharyngeal carcinoma diagnosis and chemoradiotherapy response using serum endogenous small molecules profiling.2024Journal of pharmaceutical and biomedical analysis
  14. Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study.2024Oral oncology
  15. Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials.2024The Annals of pharmacotherapy
  16. Anatomical studies and early results on endoscopic transoral medial pterygomandibular fold approach to salvage retropharyngeal lymphadenectomy in nasopharyngeal carcinoma.2024The Journal of laryngology and otology
  17. Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 immunotherapy in advanced recurrent nasopharyngeal carcinoma.2023BMC cancerFree full text
  18. Changes in brain gray matter volume in nasopharyngeal carcinoma patients after radiotherapy in long-term follow-up.2023Brazilian journal of otorhinolaryngologyFree full text
  19. Elderly nasopharyngeal carcinoma patients (aged ≥70 years): Survival and treatment strategies.2023Cancer medicineFree full text
  20. Pretreatment dual-energy CT for predicting early response to induction chemotherapy and survival in nasopharyngeal carcinoma.2023European radiology
  21. Innovative Fudan rT staging in endoscopic surgery for recurrent nasopharyngeal carcinoma.2023Head & neck
  22. Endoscopic surgery is superior to intensity-modulated radiotherapy in the treatment of advanced recurrent nasopharyngeal carcinoma.2023International forum of allergy & rhinology
  23. Salvage endoscopic surgery for skull base osteoradionecrosis in nasopharyngeal carcinoma patients: A prospective, observational, single-arm clinical study.2023Rhinology
  24. Transoral robotic resection of advanced recurrent nasopharyngeal carcinoma involving the internal carotid artery.2023The international journal of medical robotics + computer assisted surgery : MRCAS
  25. Circular RNAs: Functions and mechanisms in nasopharyngeal carcinoma.2022Head & neck
  26. Authors' reply - "Innovative application of internal carotid artery embolization in salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma: A case-matched comparison".2022International forum of allergy & rhinology
  27. Salvage Endoscopic Nasopharyngectomy in Recurrent Nasopharyngeal Carcinoma: Prognostic Factors and Treatment Outcomes.2021American journal of rhinology & allergy
  28. Identification of key pseudogenes in nasopharyngeal carcinoma based on RNA-Seq analysis.2021BMC cancerFree full text
  29. Circular RNA TGFBR2 acts as a ceRNA to suppress nasopharyngeal carcinoma progression by sponging miR-107.2021Cancer letters
  30. Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?2021Frontiers in immunologyFree full text
  31. Establishment and validation of a novel nomogram to predict overall survival in nasopharyngeal carcinoma with lymph node metastasis.2021Head & neck
  32. Nano-Coated si-SNHG14 Regulated PD-L1 Expression and Decreased Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells.2021Journal of biomedical nanotechnology
Chinese-language papers (not in the count)9
  1. [Transfer learning-based endoscopic image recognition of nasopharyngeal carcinoma: investigating pre-trained large models in small sample settings].2025Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  2. [Endoscopic transoral approach nasopharyngectomy for petroclival and jugular foramen nasopharyngeal carcinoma].2023Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  3. [The application of submental flap in the nasopharyngectomy for nasopharyngeal carcinoma].2022Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgeryFree full text
  4. [Analysis of clinical prognosis of endoscopic salvage surgery in patients with rT2 recurrent nasopharyngeal carcinoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  5. [Prevention and management of complications in endoscopic recurrent nasopharyngeal carcinoma surgery].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  6. [Internal carotid artery embolization in endoscopic salvage surgery for recurrent nasopharyngeal carcinoma: a single-center retrospective study].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  7. [The application of temporalis muscle flap in the salvage nasopharyngectomy for advanced recurrent nasopharyngeal carcinoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  8. [Surgical treatment of recurrent nasopharyngeal carcinoma: promise and challenge].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  9. [Application of pedicle nasoseptal flap in endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma: an analysis of 39 cases].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
All its trials on ClinicalTrials.gov, any status14
  1. Adjuvant vs Surgery Only in Early-stage Recurrent NPCRecruitingNCT06228079Lead sponsorPhase 3Start 2024-06
  2. Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPCRecruitingNCT06235203Lead sponsorPhase 3Start 2024-07
  3. Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRTNot yet recruitingNCT04215510Lead sponsorPhase 3Start 2021-03
  4. Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPCStatus unknownNCT05350891Lead sponsorPhase 2Start 2022-05
  5. Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic ImagesStatus unknownNCT05627310Lead sponsorStart 2022-11
  6. Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal CarcinomaStatus unknownNCT05011227Lead sponsorPhase 2Start 2021-08
  7. The Diagnosis of NPC Using the Probe-based Confocal Laser EndomicroscopyStatus unknownNCT03202173Lead sponsorN/AStart 2017-01
  8. Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.RecruitingNCT07781358Lead (inferred)Phase 2Start 2026-08
  9. PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction ChemotherapyStatus unknownNCT06156878Lead (inferred)Phase 2Start 2022-08
  10. Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT04921995Lead (inferred)Phase 2Start 2019-04
  11. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Study sitePhase 3Start 2025-12
  12. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  13. Individualized Neck Cervical Irradiation Prophylaxis Trial of NPCRecruitingNCT07303023Study sitePhase 3Start 2025-09
  14. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02944708Study sitePhase 3Start 2015-10
More papers found outside PubMed (not counted)11
  1. 666O Exploration of the efficacy of nimotuzumab combined with induction chemotherapy in locally advanced nasopharyngeal carcinoma: A multicenter, prospective phase III study2025Annals of Oncologyarticle
  2. EGCG suppresses nasopharyngeal carcinoma progression by reducing PACRG methylation via inhibition of DNA methyltransferases2025Archives of Medical Sciencearticle
  3. Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: A phase 2 randomized clinical trial.2025Journal of Clinical Oncologyarticle
  4. Topology-Aware Wavelet Mamba for Airway Structure Segmentation in Postoperative Recurrent Nasopharyngeal Carcinoma CT Scans2025arXiv (Cornell University)preprint
  5. Vision-language foundation model for generalizable nasal disease diagnosis using unlabeled endoscopic records2025Pattern Recognitionarticle
  6. WITHDRAWN: 1440TiP Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine(GX) versus tislelizumab plus gemcitabine/cisplatin(GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multic2025Annals of Oncologyretraction
  7. Effect of perioperative medical therapy on prognosis in recurrent nasopharyngeal carcinoma: A comparative effectiveness research.2024Journal of Clinical Oncologyconference-abstract
  8. Establishment of Endoscopic Surgical Innovative System of Recurrent Nasopharyngeal Carcinoma2022DOAJ (DOAJ: Directory of Open Access Journals)article
  9. Myocardin immunohistochemistry index is associated with clinical prognosis in nasopharyngeal carcinoma: a clinical practice-based cohort study2022Tropical Journal of Pharmaceutical Researcharticle
  10. Tislelizumab Rechallenge for Recurrent or Metastatic Nasopharyngeal Carcinoma (RM-NPC) Previously Treated with Another Anti-PD1 Antibody2022International Journal of Radiation Oncology*Biology*Physicsarticle
  11. Deep Convolutional Neural Networks for Accurate Diagnosis of Nasopharyngeal Carcinoma in pCLE Images2021International Conference on Networking Systems of AI (INSAI)conference-paper

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 6 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 2.0%.

Papers led
6
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 3320242025: 112025

11 hospitals in Shanghai for retinoblastoma176 hospitals in China for retinoblastoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
    Phase
    Early phase 1
    Started
    2025-04
    Registry
    NCT06972602

    Age 1 year to 12 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan UniversityShanghai

  2. Recruiting
    Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT06424301

    Age 6 months to Not stated (registered criteria)

    Led by Eye & ENT Hospital of Fudan UniversityShanghai

  3. Recruiting
    Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
    Phase
    N/A
    Started
    2021-05
    Registry
    NCT04903678

    Age not stated (registered criteria)

    Led by Eye & ENT Hospital of Fudan UniversityShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmologyENT / head & neck surgery
Papers it led6
  1. Role of additional topotecan injections (plus two) in reducing recurrence rate in retinoblastoma of group D and group E patients: a retrospective study.2025BMJ open ophthalmology
  2. Assessment of Retinal Microvasculature and Choroidal Vascularity After Intra-arterial Chemotherapy for Retinoblastoma.2024American journal of ophthalmology
  3. Low expression of NR1D1 and NR2E3 is associated with advanced features of retinoblastoma.2024International ophthalmology
  4. Multimodal Imaging of a Retinocytoma.2024Ophthalmology. Retina
  5. E2F1/CKS2/PTEN signaling axis regulates malignant phenotypes in pediatric retinoblastoma.2022Cell death & disease
  6. Quantitative evaluation of retinal microvasculature and retrobulbar vessels after intravenous chemotherapy for retinoblastoma.2021BMC ophthalmology
Chinese-language papers (not in the count)2
  1. [The efficacy of topotecan versus topotecan combined with melphalan in the treatment of vitreous seeds in retinoblastoma].2025[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  2. [Clinical features of patients with retinocytoma].2021[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
Earlier papers (2016–2020)4
  1. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients.2019BMC ophthalmology
  2. Retrobulbar ocular blood flow changes measured by colour Doppler imaging after intra-arterial chemotherapy in retinoblastoma.2017The British journal of ophthalmology
  3. [Short-term efficacy of intravitreal injection of melphalan for refractory vitreous seeding from retinoblastoma].2017[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  4. [Eyeball salvage treatment or enucleation for advanced retinoblastoma].2016[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
All its trials on ClinicalTrials.gov, any status3
  1. High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous SeedRecruitingNCT06972602Lead sponsorEarly phase 1Start 2025-04
  2. Targeting NUDT21 siRNA Drugs for Patients With Refractory RetinoblastomaRecruitingNCT06424301Lead sponsorEarly phase 1Start 2024-12
  3. Intrathecal Chemotherapy for Central Nervous System Metastasis in RetinoblastomaRecruitingNCT04903678Lead sponsorN/AStart 2021-05

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

14 hospitals in Shanghai for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 5 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
5
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 3320242025: 112025

27 hospitals in Shanghai for neuroblastoma321 hospitals in China for neuroblastoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06255210

    Age 18 years to Not stated (registered criteria)

    Led by Eye & ENT Hospital of Fudan UniversityShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersENT / head & neck surgeryRadiation oncologyRadiology / nuclear medicine
Papers it led5
  1. Deep learning models for differentiating three sinonasal malignancies using multi-sequence MRI.2025BMC medical imaging
  2. Survival Analysis and Prognostic Factors After Endonasal Resection of Advanced Olfactory Neuroblastomas: A Single Institution Experience.2024Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  3. Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity.2024Nature cancer
  4. The value of elective neck irradiation in management of esthesioneuroblastoma: a retrospective study based on propensity score matching.2024Radiation oncology (London, England)
  5. The prognostic value of S-100 protein and Ki-67 index in olfactory neuroblastoma.2022Japanese journal of clinical oncology
Earlier papers (2016–2020)5
  1. Prognostic factors and outcomes of multimodality treatment in olfactory neuroblastoma.2020Oral oncology
  2. Neck management in patients with olfactory neuroblastoma.2020Oral oncology
  3. Management of orbital invasion in esthesioneuroblastoma: 14 years' experience.2019Radiation oncology (London, England)
  4. Intravoxel incoherent motion MRI for differentiating sinonasal small round cell malignant tumours (SRCMTs) from Non-SRCMTs: comparison and correlation with dynamic contrast-enhanced MRI.2018Clinical radiology
  5. Differentiation of olfactory neuroblastomas from nasal squamous cell carcinomas using MR diffusion kurtosis imaging and dynamic contrast-enhanced MRI.2018Journal of magnetic resonance imaging : JMRI
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)RecruitingNCT06255210Lead (inferred)Phase 2Start 2024-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Shanghai for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Takayasu arteritis presenting as isolated anterior ischemic optic neuropathy.2018International ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

14 hospitals in Shanghai for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Shanghai for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

复旦大学附属眼耳鼻喉科医院

Eye & ENT Hospital of Fudan University

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Affiliated Eye Ear Nose and Throat Hospital; Eye and ENT Hospital of Fudan University; Eye Ear Nose and Throat Hospital; Fudan University Eye Ear Nose and Throat Hospital; Fudan Eye & ENT Hospital; Shanghai Eye and ENT Hospital

Suggest a correctionDownload the data